Rankings
▼
Calendar
RXRX FY 2025 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RXRX
Recursion Pharmaceuticals, Inc.
$2B
FY 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$75M
+26.9% YoY
Gross Profit
-$46M
-62.0% margin
Operating Income
-$648M
-867.9% margin
Net Income
-$645M
-863.4% margin
EPS (Diluted)
$-1.44
Cash Flow
Operating Cash Flow
-$372M
Free Cash Flow
-$378M
Stock-Based Comp.
$111M
Balance Sheet
Total Assets
$1.5B
Total Liabilities
$343M
Stockholders' Equity
$1.1B
Cash & Equivalents
$743M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$75M
$59M
+26.9%
Gross Profit
-$46M
$14M
-440.2%
Operating Income
-$648M
-$479M
-35.3%
Net Income
-$645M
-$464M
-39.1%
← Q4 2024
All Quarters
Q1 2025 →